Experience

Xilio Therapeutics, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Principal Scientist

  • Jul 2023 - 6 months

  Waltham, Massachusetts, United States • Led internal developability studies of antibody, cytokine, and hetero-oligomeric fusion proteins as a part of research-to-development transition to CMC team. • Generated data which enabled nomination of development candidate in four projects.

• Senior Scientist

  • Jul 2021 - Jun 2023

  Waltham, Massachusetts, United States • Developed and executed accelerated, plasma, pH, methionine/tryptophan oxidation, manufacturability, and pre-formulation stability studies and platforms. • Tested mutations for reducing aggregation, increasing thermal stability, and increasing glycosylation homogeneity in discovery-stage projects. • Developed DSC, SEC-MALS, RP, HIC, and cIEF methods for characterization. • Trained and managed full-time Northeastern University co-op student for six months. • Managed CRO for HDX… Show more • Developed and executed accelerated, plasma, pH, methionine/tryptophan oxidation, manufacturability, and pre-formulation stability studies and platforms. • Tested mutations for reducing aggregation, increasing thermal stability, and increasing glycosylation homogeneity in discovery-stage projects. • Developed DSC, SEC-MALS, RP, HIC, and cIEF methods for characterization. • Trained and managed full-time Northeastern University co-op student for six months. • Managed CRO for HDX structural analysis of multi-domain proteins. • Managed student, full-time direct report or 6 months in biophysical techniques and biotech R&D process.

• Scientist

  • Jan 2020 - Jun 2021

  Waltham, Massachusetts, United States • Characterized antibody, cytokine, and heterotrimeric fusion proteins for stability, purity, and homogeneity. • Qualified DSF to study thermal stability of proteins with different domains, mutations, and buffers. • Optimized CE-SDS method for quantification of active, product-related impurities. • Won “X-Nihilo” Team Award ($2,500) for implementation of new analytical techniques and contributions to IL-15 project.



Takeda

• Biotechnology
• 1 - 100 Employee

• Scientist

  • Jan 2019 - Dec 2019

  Cambridge, MA • Developed MST binding assay for small molecule hit validation of enzyme target. • Optimized cIEF for charge profiling of engineered antibody variants and enzyme replacement therapies. • Utilized DSF to study thermal stability of proteins with different mutations, buffers, and concentrations.



Northwestern University - The Feinberg School of Medicine

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Researcher in Biophysical Characterization

  • Jul 2018 - Dec 2018

  Greater Chicago Area • Led and executed structural and biophysical characterization of the intrinsically mixed-folded, human kinetochore protein (Cdt1) using spectroscopy, scattering, and chromatography. • Established milligram-scale protein purification capabilities to enable protein structural studies in a cell biology lab. • Simulated ensemble conformations of mixed folded/unfolded protein using rigid body modeling. • Trained and mentored part-time student in biophysical techniques and manuscript… Show more • Led and executed structural and biophysical characterization of the intrinsically mixed-folded, human kinetochore protein (Cdt1) using spectroscopy, scattering, and chromatography. • Established milligram-scale protein purification capabilities to enable protein structural studies in a cell biology lab. • Simulated ensemble conformations of mixed folded/unfolded protein using rigid body modeling. • Trained and mentored part-time student in biophysical techniques and manuscript writing.

• PhD Candidate in Structural Biology

  • Sep 2012 - Jun 2018

  Chicago, Illinois • Developed and optimized protein purification for milligram-scale production of proteins using IMAC, AEX, CEX, and SEC. • Solved crystal structure and generated multi-domain model of a novel mitochondrial GTPase (Miro), with implications in neurological diseases. • Calculated NMR structure of novel mitochondrial-modulating protein (VopE), with implications in V. cholerae infection. • Led meta-analysis to study phosphorylation sites near drug binding sites on proteins in the PDB.



Genentech

• United States
• Biotechnology Research
• 700 & Above Employee

• Intern in Early Discovery Biochemistry

  • Jul 2015 - Oct 2015

  South San Francisco • Optimized a codon replacement strategy to incorporate unnatural amino acids into phage displayed peptides. • Screened and discovered specific binding peptides for epigenetic drug targets.



Johns Hopkins Drug Discovery

• Intern in Medicinal Chemistry

  • Jan 2011 - Sep 2012

  Baltimore, MD • Synthesized substrate analogues for use in drug screening as GCPII inhibitors with implications in cancer and peripheral neuropathy • Optimized whole-cell xc- antiporter inhibition assays for use in high-throughput screening



University of Cambridge

• United Kingdom
• Research Services
• 700 & Above Employee

• Intern in Chemical Biology

  • May 2011 - Aug 2011

  Cambridge, United Kingdom • Expressed and produced protein complex mutants with desirable ligand interactions based on crystal structures